JP2011527704A5 - - Google Patents

Download PDF

Info

Publication number
JP2011527704A5
JP2011527704A5 JP2011517646A JP2011517646A JP2011527704A5 JP 2011527704 A5 JP2011527704 A5 JP 2011527704A5 JP 2011517646 A JP2011517646 A JP 2011517646A JP 2011517646 A JP2011517646 A JP 2011517646A JP 2011527704 A5 JP2011527704 A5 JP 2011527704A5
Authority
JP
Japan
Prior art keywords
independent
groups
weight
alkyl
transcutol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011517646A
Other languages
English (en)
Japanese (ja)
Other versions
JP5596680B2 (ja
JP2011527704A (ja
Filing date
Publication date
Priority claimed from US12/171,515 external-priority patent/US8026271B2/en
Application filed filed Critical
Publication of JP2011527704A publication Critical patent/JP2011527704A/ja
Publication of JP2011527704A5 publication Critical patent/JP2011527704A5/ja
Application granted granted Critical
Publication of JP5596680B2 publication Critical patent/JP5596680B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011517646A 2008-07-11 2009-07-10 経口抗がん製剤 Expired - Fee Related JP5596680B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/171,515 US8026271B2 (en) 2008-07-11 2008-07-11 Formulations of indol-3-yl-2-oxoacetamide compounds
US12/171,515 2008-07-11
PCT/US2009/050210 WO2010006234A2 (en) 2008-07-11 2009-07-10 Anticancer oral formulation

Publications (3)

Publication Number Publication Date
JP2011527704A JP2011527704A (ja) 2011-11-04
JP2011527704A5 true JP2011527704A5 (https=) 2012-08-16
JP5596680B2 JP5596680B2 (ja) 2014-09-24

Family

ID=41505721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011517646A Expired - Fee Related JP5596680B2 (ja) 2008-07-11 2009-07-10 経口抗がん製剤

Country Status (8)

Country Link
US (1) US8026271B2 (https=)
EP (1) EP2310363B1 (https=)
JP (1) JP5596680B2 (https=)
KR (1) KR101627382B1 (https=)
CN (1) CN102159541B (https=)
ES (1) ES2426599T3 (https=)
TW (1) TWI384984B (https=)
WO (1) WO2010006234A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8026271B2 (en) * 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
KR101763656B1 (ko) 2009-06-29 2017-08-01 인사이트 홀딩스 코포레이션 Pi3k 저해물질로서의 피리미디논
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
TW201130842A (en) * 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
EP3660016A1 (en) 2010-12-20 2020-06-03 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
HUE044867T2 (hu) 2011-05-12 2019-11-28 Proteostasis Therapeutics Inc Proteosztázis szabályzók
PT3513793T (pt) 2011-09-02 2021-05-10 Incyte Holdings Corp Heterociclilaminas como inibidores de pi3k
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
SG10201907576SA (en) 2015-02-27 2019-09-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
SG11202011680YA (en) 2018-06-01 2020-12-30 Incyte Corp Dosing regimen for the treatment of pi3k related disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
TWI323658B (en) * 2001-12-06 2010-04-21 Nat Health Research Institutes Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same
BRPI0518484A2 (pt) * 2004-11-24 2008-11-18 Merck & Co Inc composiÇço, cÁpsula, e, processo para preparar a mesma
US20060134204A1 (en) * 2004-12-21 2006-06-22 Wong Patrick S Complexes made using low solubility drugs
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
BRPI0717721A2 (pt) * 2006-11-28 2013-10-29 Marinus Pharmaceuticals "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
EP2121139B1 (en) * 2007-01-16 2012-10-10 BiPar Sciences, Inc. Formulations for cancer treatment
US8026271B2 (en) * 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds

Similar Documents

Publication Publication Date Title
JP2011527704A5 (https=)
Lee et al. Polymer structure and conformation alter the antigenicity of virus-like particle–polymer conjugates
RU2485942C2 (ru) Бупропиона гидробромид и его терапевтические применения
CN101410098B (zh) 包括含亲脂性药物的纳米胶囊的微球
JP7602324B2 (ja) 重水素化ドンペリドン組成物、方法、及び調製
CN103260741B (zh) 本体肠溶胶囊壳
JP2010523553A5 (https=)
JP2012502037A5 (https=)
JP2015503593A5 (https=)
JP2015515962A (ja) 放出制御ポリマーの水性分散液並びにそのシェル及びカプセル
CN100500137C (zh) 用于片剂和囊片的膜包衣
JP2005514386A5 (https=)
JP2011225600A5 (https=)
JP2010501632A (ja) 高安定性を示すソフトカプセルにおけるアセチルサリチル酸又はその誘導体の製剤
JP2019526537A5 (https=)
JP2014534196A5 (https=)
JP2007537258A5 (https=)
CA2633924A1 (en) Gastric reflux resistant dosage forms
JP2011088926A5 (https=)
RU2014149010A (ru) Форма многослойного покрытия фармацевтической композиции для перорального применения, содержащей омега-3 жирную кислоту или ее алкиловый сложный эфир, а также лекарственное средство на основе статина
JP2007526238A5 (https=)
JP2009544665A5 (https=)
CN1759829A (zh) 一种度洛西汀肠溶微丸胶囊及其制备方法
JP2011046708A5 (https=)
JP2007505105A5 (https=)